摘要:
目的 观察氨溴索注射液联合环丙沙星注射液治疗铜绿假单胞菌耐药下呼吸道感染的临床疗效及安全性.方法 将68例铜绿假单胞菌耐药下呼吸道感染者随机分为对照组34例和试验组34例.对照组予以头孢哌酮钠舒巴坦钠每次3.0g,tid,静脉输注;试验组在对照组治疗的基础上,予以氨溴索每次30mg,tid,雾化吸入+环丙沙星每次0.6g,qd,静脉滴注.2组患者均治疗14 d.比较2组患者的临床疗效、细菌清除率和药物不良反应的发生情况.结果 治疗后,试验组和对照组的总有效率分别为91.18%(31例/34例)和70.59% (24例/34例),细菌清除率分别为94.12%(32例/34例)和76.47%(26例/34例),差异均有统计学意义(均P <0.05).试验组发生的药物不良反应有胃肠道反应和血压突然升高,对照组发生的药物不良反应有胃肠道反应和发热.试验组和对照组的总药物不良反应发生率分别为20.59%和14.71%,差异无统计学意义(P>0.05).结论 氨溴索注射液联合环丙沙星注射液治疗铜绿假单胞菌耐药下呼吸道感染的临床疗效确切,其能显著提高细菌清除率,且不增加药物不良反应发生率.%Objective To observe the clinical efficacy and safety of ambroxol injection combined with ciprofloxacin injection in the treatment of lower respiratory tract infection associated with drug-resistant Pseudomonas aeruginosa.Methods A total of 68 patients with lower respiratory tract infection associated with drug-resistant Pseudomonas aeruginosa were randomly divided into control and treatment groups with 34 cases per group.Control group was treated with cefoperazone sodium and sulbactam sodium 3 g per time,tid,intravenous infusion.Treatment groups was treated with ambroxol 30 mg per time,tid,nebulization inhalation + ciprofloxacin 0.6 g per time,qd,intravenous drip,on the basis of control group.Two groups were treated for 14 d.The clinical efficacy,bacterial clearance rate and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates of the treatment and control groups were 91.18% (31 cases / 34 cases) and 70.59% (24 cases / 34 cases),the bacterial clearance rates of the treatment and control groups were 94.12% (32 cases / 34 cases) and 76.47% (26 cases / 34 cases),the differences were statistically significant (all P < 0.05).The adverse drug reactions of treatment group were gastrointestinal reaction and sudden elevation of blood pressure,which in control group were gastrointestinal reaction and fever.The incidences of adverse drug reactions in treatment and control groups were 20.59% and 14.71% without significant difference (P >0.05).Conclusion Ambroxol injection combined with ciprofloxacin injection has definitive clinical efficacy in the treatment of lower respiratory tract infection associated with drug-resistant Pseudomonas aeruginosa,which can significantly increase the bacterial clearance rate,without increasing the incidence of adverse drug reactions.